Connetics' Olux-E (clobetasol propionate) foam, 0.05%, was approved for treating inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Drug Criteria & Outcomes: New FDA Approvals
Drug Criteria & Outcomes
FDA recently approved these drugs:
- Connetics' Olux-E (clobetasol propionate) foam, 0.05%, was approved for treating inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. FDA noted the company has already fulfilled the pediatric study requirement for the application, and reminded the company of its commitments to perform two post-marketing studies: a dermal carcinogenicity study and a photocarcinogenicity study.
- Shire's Lialda (mesalamine) delayed release tablets, 1.2g, was approved for induction of remission in patients with active, mild to moderate ulcerative colitis. FDA said Lialda's safety and effectiveness beyond eight weeks has not been established. The company is required to perform a post-marketing pediatric study for treating ulcerative colitis in children of all ages.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.